chemoradiotherapy

Advancing Adjuvant Therapy in Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: Promising Results from Immunochemoradiation Trial

By MedXY 08/23/2025

The ACCORD trial demonstrates that combining camrelizumab with chemoradiotherapy significantly improves survival outcomes in resectable extrahepatic cholangiocarcinoma and gallbladder cancer, with an acceptable safety profile.

Clinical Updates Wellness & Lifestyle

Sequential Chemoradiotherapy vs Induction Plus Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Efficacy and Safety Insights from a Phase 3 Randomized Trial

By MedXY 08/23/2025

A multicenter phase 3 trial demonstrates that sequential chemoradiotherapy is noninferior to induction plus concurrent chemoradiotherapy for stage III/IVA nasopharyngeal carcinoma with fewer acute toxicities.

Clinical Updates Wellness & Lifestyle

Comparative Efficacy of Induction-Concurrent Versus Concurrent-Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial

By MedXY 08/23/2025

A phase 3 trial showed no significant difference in 3-year progression-free survival between induction-concurrent and concurrent-adjuvant chemoradiotherapy in treating high-risk N2-N3 nasopharyngeal carcinoma, with both regimens exhibiting manageable safety profiles.

Clinical Updates Wellness & Lifestyle

Dual Immune Checkpoint Blockade with Neoadjuvant Chemoradiotherapy in Rectal Cancer: Insights from the CHINOREC Trial

By MedXY 08/23/2025

The CHINOREC phase 2 trial demonstrates that adding ipilimumab and nivolumab to standard neoadjuvant chemoradiotherapy in rectal cancer is safe and feasible, showing promising clinical activity but no significant improvement in complete response rates.